Working… Menu

This is a 30-month, Phase III, Multicenter, Randomized, Double-masked, Sham-injection Controlled Study to Assess the Efficacy and Safety of Multiple IVT Injections of APL-2 in Subjects With GA Secondary to AMD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03525613
Recruitment Status : Recruiting
First Posted : May 15, 2018
Last Update Posted : September 13, 2019
Information provided by (Responsible Party):
Apellis Pharmaceuticals, Inc.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : April 30, 2021
Estimated Study Completion Date : December 30, 2022